UK biotech stocks rise on hepatitis C elimination milestone
Resolves: Gilead Sciences or another UK-listed biotech firm's stock price increases by 5% or more within 3 months of England announcing full hepatitis C elimination.
user-generated· earnings
UK biotech stocks rise on hepatitis C elimination milestone
Market overview
Gilead Sciences and other UK-listed biotech firms surge as England nears hepatitis C elimination.
earnings prediction market
- Implied probability (Yes)
- 70%
- Closes
- 2026-12-31
About this prediction
Resolution criteria
Gilead Sciences or another UK-listed biotech firm's stock price increases by 5% or more within 3 months of England announcing full hepatitis C elimination.
Source: user-generated
More earnings markets
- Palo Alto Networks will sustain mid-teens revenue growth in 2027 — 65% Yes
- Mind Robotics IPO within 18 months — 75% Yes
- Cloudflare's AI-driven product revenue exceeds 30% by 2027 — 60% Yes
- Zebra Technologies Q2 2026 earnings beat consensus by ≥5% — 75% Yes
- Griffin's financial support boosts Rubio’s early primary fundraising by 40% — 65% Yes
- Subversive Ex-Elon ETFs QQNE and SPNE will outperform their benchmark indices by 5%+ within 6 months — 72% Yes
- Shell's trading desk revenue exceeds $1.5B in Q2 2026 — 75% Yes
- GM's AI hiring push lags internal AI project deadlines — 68% Yes
No one's made a Conviction call on this yet. Be the first to call it →
Loading…